This Million Targets Drug: A $7M Bet on a CNS Breakthrough
A focused look at a $7 million wager on a CNS drug maker in Phase 3. Learn what this move signals about biotech momen...
Understanding the value of points versus cash back helps you make smart financial choices. Compare both to see which is more beneficial.
28,655 articlesA focused look at a $7 million wager on a CNS drug maker in Phase 3. Learn what this move signals about biotech momen...
Warner Bros. Discovery has formally labeled Paramount Skydance’s all-cash bid superior to Netflix’s, kicking off a sh...
As AI rivals surge and cloud demand shifts, investors question Microsoft’s staying power in the Magnificent 7. The de...
Palantir has cooled off after a blazing run, but analysts say there's still meaningful upside. This guide breaks down...
A prominent fiduciary family office recently exited a sizable international value ETF position, prompting questions a...
CoreWeave stock tumbling today underscores the volatility in AI infrastructure plays. This explainer breaks down what...
Space infrastructure hurdles are shrinking as Redwire reports stronger backlog and new contracts. This week, redwire ...
A roundup of Thursday’s best wall street analyst calls highlights notable upgrades and price targets across Brown-For...
Geopolitical headlines sparked a wild crypto swing. Bitcoin briefly climbed toward the $70K mark as traders weighed r...
A growing mismatch in mortgage underwriting is leaving many retirees with fewer loan options. New data show denial ra...
Capri Holdings saw a notable insider purchase when the CEO bought 55,000 shares. This article breaks down what it cou...
As Aug. 5 looms, investors debate whether Moderna belongs in a refreshed portfolio. This guide breaks down the cataly...